drugset / Trial / NCT02556268
Interaction With HIV Antiretroviral Agents
Non-randomizedParallel-groupOpen-labelOther
Summary
To investigate the pharmacokinetic drug-drug interaction potential of fixed dose antiretroviral therapies, i.e. ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved antiretroviral protease inhibitor in combination with (preferably) TRIUMEQ, on the exposure to riociguat in HIV patients on a stable dose of one of these therapies. • To Assess the safety and tolerability of riociguat treatment in combination with these fixed-dose antiretroviral therapies.
Timeline
- Start
- 2016-02-23
- Primary completion
- 2016-12-07
- Completion
- 2016-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Riociguat | Other / unclassified | 0.5 mg | Oral |
| Background | Abacavir | Other / unclassified | 600 mg | — |
| Background | Atazanavir | Other / unclassified | — | — |
| Background | Cobicistat | Small molecule | 150 mg | — |
| Background | Darunavir | Small molecule | — | — |
| Background | Dolutegravir | Other / unclassified | 50 mg | — |
| Background | Efavirenz | Other / unclassified | 600 mg | — |
| Background | INDINAVIR ANHYDROUS | Other / unclassified | — | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Rilpivirine | Small molecule | 25 mg | — |
| Background | Ritonavir | Other / unclassified | — | — |
| Background | Saquinavir | Small molecule | — | — |
| Background | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |
| Background | elvitegravir | Small molecule | 150 mg | — |
| Background | emtricitabine | Other / unclassified | 200 mg | — |
Indications
No indication recorded.